Given the prominent tumor-to-background ratios observed in HER2-positive breast xenografts compared to HER2-positive ectopic tumors based on biodistribution, we investigated the SUV differences between tumor uptake in HER2-positive cell lines inoculated at orthotopic versus ectopic sites. The gene discussed is ERBB2; the disease is neoplasm.